午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook >> CAS DataBase List >>Zopiclone Impurity

Zopiclone Impurity

CAS No.
865061-50-3
Chemical Name:
Zopiclone Impurity
Synonyms
3-formylpyrazine-2-carboxylic acid;2-Pyrazinecarboxylic acid, 3-formyl-
CBNumber:
CB46187242
Molecular Formula:
C6H4N2O3
Molecular Weight:
152.11
MDL Number:
MOL File:
865061-50-3.mol
Last updated:2023-05-15 10:43:51

Zopiclone Impurity Properties

Boiling point 354.2±42.0 °C(Predicted)
Density 1.519±0.06 g/cm3(Predicted)
solubility Methanol (Slightly), Water (Slightly)
pka 3.28±0.10(Predicted)
form Solid
color Pale Pink to Light Red

Zopiclone Impurity Chemical Properties,Uses,Production

Uses

7-Hydroxy-furo[3,4-b]pyrazin-5-one is a derivative of 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one (C379925) which is an impurity of Eszopiclone (E889150), a nonbenzodiazepine hypnotic agent used as a treatment for insomnia.

Zopiclone Impurity Preparation Products And Raw materials

Raw materials

Preparation Products

Zopiclone Impurity Suppliers

Global( 4)Suppliers
Supplier Tel Email Country ProdList Advantage
Nanjing XiZe Biotechnology CO., Ltd. 025-66023220 0086-15250997978 1511893459@qq.com China 7892 55
Guangzhou Jiuzhi Pharmaceutical Technology Co., Ltd. 020-89854820 sales@jzpharma.cn China 1130 58
Shenzhen Roark Pharma-Tec Co., Ltd. 13128912434 2880126944@qq.com China 2577 58
Shanghai Kaisen Biotechnology Co., Ltd 17558870519 3549952815@qq.com China 1170 58
2-Pyrazinecarboxylic acid, 3-formyl- 3-formylpyrazine-2-carboxylic acid 865061-50-3
This site uses cookies
This website uses cookies and similar technologies to store and retrieve information about your use of this website. This information helps us to provide, analyse and improve our services, which may include personalised content or advertising. We may share this information with Google and other third parties. This cookies are necessary for our website to work properly . By clicking "Continue" or continuing to browse our site you are agreeing to our and our partners use of cookies.
Accept